Class 4, Class 3, and Class 2 Laser Therapy Devices

General Overview

To understand the difference between High-Intensity Laser Therapy (HILT – also known as High-Power Laser Therapy or High-Level Laser Therapy) and Low-Level Laser Therapy (LLLT), it is first important to understand their classification by the FDA:

  • HILT devices are classified as ‘Class IV Lasers’ by the FDA in virtue of having a power output that’s greater than 500mW (i.e. high risk of hazard).
  • LLLT devices are classified as either ‘Class IIIB Lasers’, ‘Class IIIR Lasers’, or ‘Class II Lasers’ in virtue of having a power output of 5-500mW, 1-5mW, or <1mW respectively (i.e. lower risk of hazard).
An woman being treated with a Photobiomodulation (PBM) Therapy device
Erchonia’s EVRL® Laser: The only LLLT device to be FDA Market Cleared for treating chronic / acute back, neck, and shoulder pain, and pain associated with surgery.

The vast majority of HILT devices have longer near-infrared (NIR) wavelengths – there is a common misconception, often propagated by the manufacturers of such devices, that high power with longer wavelengths results in:

  1. Deeper penetration, allowing for the treatment of a wider range of conditions.
  2. More efficacious results (due to the delivery of more energy into the cells).

This however, is not correct for the following well-documented reasons:

  1. Due to the high absorption rate of laser light by water at wavelengths greater than 950nm, most of the energy produced at this wavelength (or above) is absorbed before penetrating the dermis.
  2. The key principle behind Laser Therapy is to generate therapeutic effects by stimulating and enhancing specific biochemical processes within cells (c.f. ‘How Do Erchonia® Lasers for Pain Relief Work?’ FAQ). However, there is an optimal ‘dose’ of laser energy (typically 2-4 joules / cm²) required for stimulating and enhancing the desired biochemical processes – HILT devices exceed this optimal level.

Put simply, HILT devices deliver too much energy at inefficient wavelengths, resulting in a lack of efficacy and increased costs.

To add to this, the high outputs used by such devices produce painful heat sensations, further limiting their scope of treatment.

In essence, HILT devices should only be used for laser surgery and tissue ablation – the high outputs are effective for cell destruction, but are not suited for therapeutic purposes, contrary to the claims of Class IV manufacturers.

LLLT devices, on the other hand, aim to deliver energy via low output, short wavelength beams of light. The general theory is that this approach transfers the optimal amount of energy for stimulating and enhancing cell function, while not damaging cells or producing painful heat sensations.

A Photobiomodulation (PBM) Therapy Device for Pain Relief
Erchonia’s FX 635® Laser: Fully automated LLLT machine – only Photobiomodulation device to be FDA-cleared for chronic heel and back pain.

Within the LLLT sector however, some of the higher output devices still generate heat / pain. Furthermore, many devices are advertised as ‘lasers’, when in fact they are Light Emitting Diodes (LEDs) or Superluminescent Diodes (SLDs). In contrast to LEDs or SLDs, ‘true’ lasers generate monochromatic, collimated, and coherent beams of light. These three properties of true lasers make them the most effective and efficient LLLT devices (c.f. ‘How Do Erchonia® Lasers for Pain Relief Work?’ FAQ).

To separate Erchonia® from such technologies, and from HILT more generally, we say that Erchonia® lasers are ‘non-thermal, true lasers’. That is, our lasers do not produce any heat or painful sensations, and are monochromatic, collimated, and coherent (to learn more, please read Class 4 Lasers, Class 3 Lasers, and Class 2 Lasers).

An In-Depth Look at Clinical Studies

The understanding of how the human body functions in conjunction with LLLT is an advancing paradigm in modern wellness approaches. These transformative changes are encouraging a clearer understanding of the mechanism of how each new invention affects each system.

Erchonia® is not excluded from the advancing medical technology that requires continual scientific evidence of the mechanism before we can thoroughly comprehend the magnitude of the neurological and physiological changes taking place. Nevertheless, Erchonia® is one of the few Laser Therapy device manufacturers that have published peer-reviewed, double blind, controlled studies dating back over twenty years, and many clinicians and researchers are still not aware of the extensive research that has been done in the field of biophysics, bionics, photobiology, and quantum biology during the past eighty years that aid in clarity of the mechanism of laser applications.

The first milestone made in the United States for Erchonia® was an FDA approval in 2002 for the treatment of neck and shoulder pain. With this approval came a new classification of therapeutic devices, referred to as NHN, which is a category for non-heating modalities for adjunctive use in pain therapy commonly known as biostimulation, which we will address later.

Unfortunately, the vast majority of other laser companies have not adhered to such standards for their therapeutic devices and have filed what is referred to as ‘substantial equivalence’ against a laser previously granted market clearance by acceptable completion of clinical trial data.

A ‘substantial equivalence’ submission to the FDA is authored by the company or a representative of the company that is intending to obtain market clearance without conducting clinical trials. The substantial equivalence document shows the device attempting to obtain market clearance being compared against a device that already has been awarded market clearance by comparison of features and components. The company submitting a substantial equivalence document, using the features and components comparison as a catalyst, then authors a narrative explaining why the device they are vying for fits in the same category of therapeutic applications of the laser or laser(s) being compared to.

Laser Classification is a regulated feature of a laser device and is a component of comparison in a substantial equivalence submission. As recently quoted in Tunér and Hodes’s article Confounders and Magicians, classification of laser devices are determined by “…the possible risk for eye injuries, and has nothing to do with the efficiency of treatment… The classification is not only a question of output power; it has to do with wavelength, divergence of the beam, emission area, pulsing, etc.”

The FDA approval process is extremely complex – this brief explanation is simply a summary of the proceedings of receiving a laser approval, and also to show that the considerations of the approval are independent of the advertising and marketing claims which follow.

The most recent flux of laser advertising has led to a great deal of confusion pertaining to the field. Much of this confusion about the use of therapeutic lasers stems from attempting to look at laser effects from a Newtonian mechanistic perspective that has now been supplanted by non-linear dynamics and quantum physics.

Oftentimes we assume things natural from current knowledge to fit within a paradigm of healing. If this was the only approach, new and innovative applications would never be developed. The latest trend in the development, and what is commonly mistaken for proper applications of LLLT, are the influx in approvals for topical heating devices (ILY). These devices have an associated Low-Level Laser component, with the removal of the collecting lens from a High-Powered Laser, but are not Low-Level Lasers. The problem is that when you remove the collecting lens out of configuration it ceases to be a focused laser. This in essence is now just a concentrated heat lamp, which gleans to the understanding of why market clearance was so easily obtainable.

By far one the most difficult concepts of laser is the energy density or fluency. This component is what in large part relates to a nonlinear approach to understanding the applications. In the market place it is the focal point of sales that depth of penetration is somehow related to this component.

Let’s look at common myths in Laser Therapy pertaining to power and how it correlates to penetration. Several companies have claimed that you need more power to penetrate the tissue and that High-Power Lasers are putting an end to Low-Level Lasers. The scientific papers published by Erchonia® have proven this to be untrue in many studies which will be referenced in this article.

It is important to take into consideration that the FDA gave market clearance to the first high-power therapeutic laser in 2004 (two years after the first Low-Level Laser); the approved device is manufactured by a company that filed substantial equivalence from a heat lamp (ILY), and in turn was given approval for topical heating and muscle relaxation – not depth of penetration like the manufacturer claims.

To date there have been no other 510(k) market clearances granted to any other ‘High-Powered Laser’ based on their own clinical trials. Low-Level Lasers have endeavoured in more substantial clinical, cellular, and molecular trails that have not only been expensive to undertake, but time consuming; this is in part the reason for why there are still very few indications for Low-Power Lasers.

The companies marketing these high-powered laser devices proclaim that they have more power and penetrate deeper than Erchonia® devices. There is no research that proves these devices are more effective than a $600 heat lamp, not to mention that they have the exact same marketing claims and can cost up to $50,000.

There is also a question as to the long-term safety of these devices which has not been proven otherwise according to published research available. In evaluating the reference material of High-Power Lasers, almost every study referenced has been done with low-level, low-energy lasers, not high-powered devices. Research published in Lasers in Surgery and Medicine in January 2006 states that “with as little as 10 joules you can cause damage to the DNA of the cell and decrease cell viability”. The laser used in the aforementioned study was a 3mW laser with a divergent beam, and this article also stated “that since the laser used was a 3mW divergent beam it is not as harmful as a narrow parallel beam.” The research proves that even a Low-Level Laser can potentially cause damage if over treated; it would take only 1 second at 10 watts to over-stimulate to a level that can cause damage.

Another myth is that High-Power Lasers have biostimulation effects. Tiina Karu’s text titled “Ten Lectures on Basic Science of Laser Phototherapy“, highlighted a study by Rochkind et al (1988) where it was found that 540nm and 632.8nm had a strong effect on the action potential of the nerve, and 904nm, as well as CW radiation at 660nm, 830nm, 880nm, and 950nm, had no effect.

Since these wavelengths are not affecting the nerve through biostimulation they try and affect the nerve through heat which has a completely different consequence. In a statement made in Jan Tunér and Lars Hode 2002 Laser Therapy book, “biostimulation based on current clinical research is 0.5 to 1 J/cm² on an open wound and 2-4 J/cm² through overlaying skin.”

For a patient to receive the maximum of 4 joules required for biostimulation they would only need to treat the patient for 1 second with a 4 watt laser and 0.5 seconds with a 10 watt laser. This is in agreement with the Arndt-Schulz Law which states “weak stimuli excite biologic activity and strong stimuli retard this activity.”

High-Powered Lasers are used for tissue ablation, hair removal, acne, etc. The companies that produce these high-powered lasers remove the collecting lens on these devices to prevent the device from burning the skin. In addition, they have to manually scan (back and forth) the patient with these devices to keep from burning the tissue. The mechanism in which they are heating the skin proves that they are not penetrating deeper; according to the Tunér and Hode article, Confounders and Magicians where they state “because 980nm has a lower penetration capacity, more energy is absorbed in the upper part of the skin and the risk for overheating is greater.” They also state anything over “1 watt is excessive” in Laser Therapy.

An additional article titled Basic Principles of Low-Level Laser Therapy stated “super pulsing allows for deeper penetration”. The laser they were referencing was a 10 to 100 watt laser used at relatively low power which is conflicting with laser classifications due to the fact that it references a Class IV laser which is not considered low power. These Class IV lasers are the same lasers used for resurfacing and tissue ablation, but without the focusing lens, and the reason they super pulse them is because if left on the skin the laser would burn or ablate the subject. The author goes on to state “that it is well suited for medium and deep tissue, such as joints and tendons,” but offers no research or references.

Let’s look at the research. Every laser has a plateau where it reaches bio-inhibition (Farok Al-Watban has published this in several wound studies), or it reaches a point where the application of laser is no longer effecting the physiological structures that are targeted. This concept is well published and we have already talked about biostimulation and its peek. In review of the published research we observe results for different power outputs, the indications of such devices, and the consequences of excessive use. There are numerous studies and clinical results that compare different power outputs using the same wavelength only manipulating the time treated which is measured in J/cm². The first example published in Photomedicine and Laser Surgery 2006 is a study using 685nm and 830nm laser on tissue repair in tendons on mice. In this study they used different fluences and divided them into 6 groups: 2 placebo groups, 2 groups of 685nm laser (red) at 3 joules and 10 joules, and 2 groups of 830nm (infrared) laser at 3 joules and 10 joules. Then they compared the results – the best results were with the 685nm at 3 J/cm², and the results with the greatest consequence to healing were with 830nm at 10 J/cm². This study lends support to the fact that higher power and longer wavelengths do not lead to better outcomes. Similar findings have been published since at least 1989, when Shiroto stated that “an increase in irradiation dose may decrease biostimulatory effects.”

As mentioned previously, the first FDA market clearance was for chronic neck and shoulder pain. The laser in this study was a 5mW 635nm line generated beam (Erchonia®). The treatment time was a total of one 4-minute treatment. The results showed a difference in pain by 64% decrease in all patients treated in comparison to the placebo group, along with increased muscle strength and range of motion.

The second market clearance for carpal tunnel syndrome was using a 100mW 830nm laser (Microlight). In this study they treated the patient three times a week for five weeks, with each treatment for 15 minutes. At the end of the study there was a difference in pain of 6.6% between real and placebo patients (this information was taken from company submissions to the FDA).

These studies illustrate that less laser energy produces more efficient results. These were biostimulation lasers not High-Powered Lasers – there is no tangible information available with High-Powered Lasers for a therapeutic indication.

Another myth with Laser Therapy is depth of penetration which seems easily disproved from the studies already noted. In addition, a 2001 MRI study by Rodrigo Neira, M.D. published in the America Journal of Cosmetic Surgery showed that an 8mW 635nm laser that was held 6 to 8 inches from the skin could emulsify deep fat (6 cm) and break up the appearance of scar tissue. Dr. Rodrigo proved this by showing abdominal MRI at 0, 4, and 6 minutes on T-1 and T-2 weighted sequences. This was later confirmed in a 2004 study published by Robert Jackson, M.D. in the AJCS journal. These results are a stark contrast to the article published in Dynamic Chiropractic titled Basic Principles of Low-Level Laser Therapy where the author stated that “red light at 640nm has been shown to effect skin, so it might be effective in treating cuts, scars, trigger points, and acupoints. Usual depth of penetration is less than 10mm.” The author offers no research, and the two aforementioned articles prove this claim to be nothing more than a theory.

In general, there seem to be many self-proclaimed experts within the Laser Therapy sector, and the problem is they do not perform any research. There are countless studies, too numerous to list all in this article, that mention secondary effects using Low-Level Laser that do not rely on power. The fact is that there are no studies supporting High-Powered Lasers for biostimulation, and every doctor knows that if you are heating the skin you are creating free radicals which were proven in the ASLMS study in January 2006.

Common FAQs About Erchonia®

What Is the Scientific Evidence Behind Erchonia® Lasers?

All studies carried out to obtain FDA-clearance are double blind, randomised, placebo-controlled, and multi-site – the most credible research of all Laser Therapy devices on the market today.

The following list shows the clinical trials and an outline of their progress. As a company, to protect our intellectual assets, not all clinical trials we are involved with are made public so as to maintain our competitive advantage. As such, not all clinical trials are listed below.

Please note: There are hundreds of clinical studies confirming the effectiveness of Low-Level Laser Therapy (LLLT), and every year there are many new publications. Below is a list of Erchonia-specific studies for FDA-clearance.

1) Chronic Neck and Shoulder Pain / Low Level Laser — 2000 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. First study done in support of 510(k) submission, second study requested by FDA.

2) Chronic Neck and Shoulder Pain / Low Level Laser — 2001 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. Study results used to obtain FDA clearance – K012580
  2. To view NIH clinical trial records, click here.

3) Low Level Laser Light Therapy as an Aid to Liposuction and Reduction of Pain Associated With Surgery — 2004 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. Study results used to obtain FDA clearance –K041139
  2. To view NIH clinical trial records, click here.

4) Acne Vulgaris Dermatological Conditions / Low Level Laser — 2005 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. FDA clearance – K050672

5) Pain Associated With Breast Augmentation Surgery / Low Level Laser — 2007 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. Results used to obtain FDA clearance – K072206
  2. To view NIH clinical trial records, click here.

6) Non-Invasive Fat Reduction and Body Contouring – Laser Scanner Waist, Hips, and Thighs — 2009 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. Study results used to obtain FDA clearance – K082609
  2. To view NIH clinical trial records, click here.

7) Equine Wound Healing – 2011 — Sponsor, Case Study.

  1. Study completed from Nov. 2010-March 2011.
  2. Monitored by Hank Jann, DVM, MS, DACVS from Oklahoma State University.

8) Equine Wound Healing – 2011 — Sponsor, placebo controlled, clinical study.

  1. Study completed from Feb. 2011-April 2011.
  2. Monitored by Hank Jann, DVM, MS, DAVCS from Oklahoma State University.

9) Arm Circumference Reduction of the Upper Arms — 2011 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. Study results used to obtain FDA clearance – K120257
  2. Study submitted to be published 2012.
  3. To view NIH clinical trial records, click here.

10) Appearance of Cellulite (Verju Laser System) — 2012 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. FDA clearance – K130922
  2. Study submitted to be published 2013.
  3. To view NIH clinical trial records, click here.

11) Non-Invasive Body Contouring Using GLS Laser – 532 nm (Green) Trade Name Verju — 2012 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. FDA clearance – K123237
  2. Study submitted to be published 2013.
  3. To view NIH clinical trial records, click here.

12) Adjunct to Chronic Heel Pain Arising from Plantar Fasciitis Using the Erchonia FX635 Laser 2012 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. FDA clearance – K132940
  2. Study results published in the American Orthopaedic Foot & Ankle Society April 2014
  3. To view NIH clinical trial records, click here.

13) Non-Invasive Dermatological Aesthetic Treatment for Reduction of Circumference of Hips, Waist and Upper Abdomen When Applied to Individuals with a Body Mass Index (BMI) Between 30 kg/m2 and 40 kg/m2 2013 – Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. FDA clearance – K142042
  2. To view NIH clinical trial records, click here.

14) Non-Invasive Dermatological Aesthetic Treatment for the Reduction of Circumference of Hips, Waist and Thighs (Zerona-Z6 OTC) — 2012 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. FDA clearance – K143007
  2. To view NIH clinical trial records, click here.

15) Non-Invasive Dermatological Aesthetic Treatment for the Reduction of Circumference of Hips, Waist, Thighs and Upper Abdomen 6 Week Treatment Protocol (Zerona-Z6) — 2014 — Sponsor and monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.

  1. FDA clearance – K150446
  2. To view NIH clinical trial records, click here.

16) Erchonia EVRL (EVRL) – 2016

       a. while using the red diode, for adjunctive use in providing temporary relief of minor chronic neck and shoulder pain of musculoskeletal origin.

       b. and while using the violet diode, to treat dermatological conditions, and specifically indicated to treat moderate inflammatory Acne Vulgaris.

  1. FDA clearance – K152196

17) Temporary Increase of Clear Nail in Patients With Onychomycosis (e.g., Dermatophytes Trichophyton Rubrum and T. mentagrophytes, and/or Yeasts Candida Albicans, etc.) (Lunula Laser ) — 2016 — Sponsor and monitor, IRB approved, blind, placebo controlled, clinical study.

  1. FDA clearance – K153164
  2. To view NIH clinical trial records, click here.

18) Non-Invasive Dermatological Aesthetic Treatment for the Reduction of Body Circumference (Zerona-Z6) — 2016.

  1. FDA clearance – K162578

19) Market Clearance to Treat Chronic Low Back Pain (FX 635) — 2018 — Placebo-controlled, randomized, double-blind, parallel-group, multi-center clinical study.

  1. FDA clearance – K180197
  2. To view NIH clinical trial records, click here.

20) Market Clearance for Relief of Chronic Musculoskeletal Pain (FX 635) — 2019 — A collection of placebo-controlled, randomized, double-blind, parallel-group, multi-center clinical studies.

  1. FDA clearance – K190572

21) Non-Invasive Dermatological Aesthetic Treatment for the Reduction of Body Circumference in Individuals With a Body Mass Index (BMI) of up to 40 kg / m² 2019 The data used to get this approval combined all previous data Erchonia® had on 20-40 BMI patients in the green laser studies above.

How Do Erchonia® Lasers for Pain Relief Work?

While the benefits of Low-Level Laser Therapy (LLLT) have been observed in hundreds of medical studies, the exact mechanisms that lead to these results are still being explored. Although we still have a lot to learn about the effects of light energy on different types of cells, the leading theory is that LLLT generates therapeutic effects through stimulating and enhancing specific biochemical processes within cells.

More specifically, utilising the first law in photochemistry (Grotthuss-Draper law), laser energy is transferred to cytochrome c oxidase (CcO) – a respiratory energy-transducing enzyme which is involved in the electron transport chain in mitochondria. This energy transfer causes photodissociation of inhibitory nitric oxide from CcO, leading to an enhancement of enzyme activity, electron transport, mitochondrial respiration, and adenosine triphosphate (ATP) production. Consequently, by altering the cellular redox state, LLLT induces the activation of numerous intracellular signalling pathways, and alters the affinity of transcription factors concerned with cell proliferation, survival, repair, and regeneration.

Erchonia® pain relief lasers utilise true laser technology, optimising photonic energy delivery through the use of monochromatic, collimated, and coherent beams of light. That is, the light emitted by a true laser is composed from photons that have the same wavelength (monochromatic), travel in the same direction / do not disperse (collimated), and are in phase in space and time (coherent). These three properties of true lasers make them the most effective and efficient devices within the Laser Therapy sector.

Erchonia® lasers were specifically designed to deliver the optimal amount of energy required to stimulate and enhance cell function while not damaging cells or producing painful heat sensations – all of our non-thermal LLLT devices are classified as ‘Class II Lasers’ by the FDA in virtue of their low output and very low risk of hazard.

How Do Erchonia® Lasers for Fat Removal Work?

Erchonia® fat removal lasers create a small transitory pore for the fatty liquids in fat cells to seep out. The fatty liquids are then naturally flushed out through the lymphatic system.

The result is that the fat cells shrink instead of being killed. When this happens, the shrunken fat cells begin to act and function like healthy lean cells, releasing the correct messages to the brain and creating a communication effect throughout the fat organ, causing other fat cells to release their content and return their hormone responses to the positive.

Procedures that have been popular in the past (such as fat freezing) focus on the elimination of fat cells, but recent research has shown this approach to be ineffective, and in the worst-case scenario, providing counterproductive results as the fat may regenerate in other parts of the body, or worse, around the organs.

Erchonia® lasers effectively train fat cells to behave and react differently, and all without excessive heat or cooling.

How Do Erchonia® Lasers for Fungal Nail Treatment Work?

Erchonia® lasers for fungal nail treatment target onychomycosis through the use of two true laser beams (red 635nm and violet 405nm – monochromatic, collimated, and coherent).

The two wavelengths trigger a photochemical reaction, producing Reactive Oxygen Species which is converted to Hydrogen Peroxide – a natural antiseptic that kills onychomycosis.

In addition, the red 635nm wavelength induces the production of Adenosine Triphosphate (ATP) which is converted to Nitric Oxide – aiding the natural immune response in fighting the infection.

What Are the Biological Effects of Low-Level Laser Therapy (LLLT)?

Clinical studies and trials of Laser Therapy technologies indicate the following beneficial effects of Low-Level Laser Therapy (LLLT).

  1. Anti-Inflammation. LLLT creates an anti-edema effect by dilating blood vessels and activating the lymphatic drainage system (which drains swollen areas). This reduces swelling caused by trauma or inflammation.
  2. Anti-Pain (Analgesic). LLLT exerts a very beneficial effect on pain in multiple ways: It partially blocks neural transmission of pain signals to the brain; It decreases nerve sensitivity; It lessens pain by reducing edema; It helps to increase the production of high levels of painkilling chemicals such as endorphins, enkephalins, and opioids from the brain and adrenal gland.
  3. Accelerated Tissue Repair and Cell Growth. Photons of light from lasers penetrate deeply into tissues and accelerate cellular reproduction and growth. The laser light also increases the energy available to the cell by increasing ATP production so that the cell can take on nutrients faster and get rid of waste products. As a result of exposure to laser light, all cells, including the cells of tendons, ligaments, and muscles, are repaired faster.
  4. Improved Vascular Activity. LLLT significantly increases the formation of new capillaries in damaged tissue, which speeds up the healing process, closes wounds more quickly, and reduces scarring. LLLT also causes vasodilation – an increase in the diameter of blood vessels – which improves the delivery of blood and healing elements to damaged tissues.
  5. Increased Metabolic Activity. LLLT stimulates higher outputs of specific pro-healing enzymes in blood cells, along with improved oxygen and nutrient delivery.
  6. Trigger Points and Acupuncture Points. LLLT stimulates muscle trigger points and acupuncture points on a non-invasive basis, providing musculoskeletal pain relief.
  7. Reduced Fibrous Tissue Formation. LLLT reduces the formation of scar tissue following damage from cuts, scratches, burns, or surgery.
  8. Improved Nerve Function. Slow recovery of nerves in damaged tissue results in impaired sensory and motor function. LLLT speeds up the process of axonal regeneration and nerve cell reconnection, and increases the amplitude of action potentials to optimize muscle action.
  9. Immunoregulation. LLLT directly affects immunity status by stimulating the production of immunoglobulins and lymphocytes, and by improving the ease of penetration of white blood cells into damaged tissue.
  10. Faster Wound Healing. LLLT stimulates fibroblast development in damaged tissue. Fibroblasts are the building blocks of collagen, which is the essential protein required to replace old tissue or repair tissue injuries. As a result, LLLT is effective on open wounds and burns.
What Is the Difference Between Erchonia® and Other Technologies in This Market?

The efficacy of Erchonia® lasers has been scientifically proven with double blind, randomised, placebo-controlled, and multi-site studies. Many competing companies advertise their products as ‘clinically proven’, guaranteeing ‘instant results’. However, these claims are often not backed by comprehensive clinical evidence.

Several companies have FDA-clearance within the Laser Therapy sector, however, in most cases the intended use / indications of their products are quite limiting or not relevant to the marketed applications. Furthermore, these FDA-clearances are often obtained without any scientific research.

We always recommend that you ask for details of the FDA-clearances and make an informed decision. Pay particular attention to the scope of the clearance, whether it involved clinical studies, how many patients participated, were the studies placebo controlled, double blind, and randomised, how many peer reviewed published articles they have, and what the adverse reactions / side effects were – we would be happy to provide this information for you.

What Conditions Can Erchonia® Pain Relief Lasers Help With?

Erchonia® pain relief lasers can help a wide variety of patients, including: Orthopaedic pain – sprains, whiplash, muscular pain, cervical or lumbar radiculopathy, tendinitis, and carpal tunnel syndrome. Our devices have also shown positive effects on individuals with chronic conditions like arthritis and osteoarthritis, and in treating post-surgical pain; Neuropathic pain, including various types of neuralgia and diabetic neuropathy; Pain management for athletes recovering from training or injuries.

What Areas Do Erchonia® Fat Removal Lasers Treat?

Erchonia® lasers for fat removal treat overall body circumference while also allowing your clients to target stubborn areas of fat and cellulite.

Most people who undergo the treatments focus on their midriff and thighs, but the device can also target any area of subcutaneous fat, including bra strap, upper arms, jowls, knees, and more.

Are There Any Conditions Which Would Prevent Patients From Receiving the Treatments?

There are no code regulated contraindications, however, since there are no long-term evaluations on certain conditions, we do not recommend using Erchonia® non-thermal lasers on pregnant women, clients with a pacemaker, or clients with photosensitive epilepsy. We also do no recommend using our devices over an area of known cancer.

Will Erchonia® Lasers Cause Pain or Burning?

Erchonia® are true Non-Thermal Low-Level Lasers and cause no pain or health risks.

What Do Erchonia® Lasers Treat and How Are They Used?

Erchonia® lasers are used in many areas, such as 360-degree fat loss, body sculpting, cellulite reduction, pain management, pre / postsurgical healing, pre / rehabilitation, nail and skin pathologies (e.g. nail fungus and acne), and more.

Not only do our lasers treat specifics, but they also empower the body to function efficiently due to the beneficial effects they have on our cells.

Why Choose Erchonia®?

With over 25 years of experience, 16,000+ devices in the market, and 20 FDA-clearances, Erchonia® Corporation are world leaders in medical-grade Laser Therapy technology for physicians, chiropractors, physical therapists, podiatrists, osteopaths, aesthetics clinics, veterinarians, and many other types of medical / health professionals.

Erchonia® own 20 of the 23 FDA-clearances given to Low-Level Lasers, and the efficacy of our devices has been proven by multiple (level 1) double blind, randomised, placebo-controlled, and multi-site clinical studies – the most credible research in the market today.

All Erchonia® laser systems are cut from raw materials, and all of our products go through a rigorous quality control process before delivery to our customers around the world. As a company, we are 85% self-reliant in all facets of our organisation, and all of our products are FDA, ISO, OSHA, and MDSAP compliant.

The Erchonia® mission statement is simply “Quality Not Compromise”, and this is ingrained in every aspect of our business – from an unwavering belief in the limitless potential applications of Low-Level Lasers, down to the care and quality of the smallest component of our devices. Just pick up any Erchonia® product, feel the quality of workmanship, and see the attention to detail that can only come from Erchonia’s near-complete control of the manufacturing and assembly processes that go into each product bearing the Erchonia® name. Read More